China Medical Technologies, a China-based in-vitro diagnostic (IVD) company, has received the State Food and Drug Administration of China (SFDA) approval for its real-time PCR-based Epidermal Growth Factor Receptor (EGFR PCR) assay for the use of lung cancer targeted drugs.

The EGFR PCR Assay is used for the detection of the 28 most common somatic mutations in the EGFR gene of patients with non-small cell lung cancer (NSCLC) and provides a qualitative assessment of mutation status to determine the use of lung cancer targeted drugs for patients.

China Medical Technologies chairman and CEO Xiaodong Wu said that they plan to offer more products on PCR platform to top tier hospital customers served by direct sales network and the company offers a comprehensive portfolio of molecular diagnostic products including FISH probes, SPR-based DNA chips and PCR-based assays.